OSE Immuno

Explore OSE Immunotherapeutics’ latest breakthroughs in immunotherapy, from ovarian cancer trials to novel antibody therapies and strategic partnerships.

OSE Immuno shifts focus to chronic pouchitis and hidradenitis suppurativa with Lusvertikimab amid volatile stock and negative earnings, exploring a risky yet promising niche in biotech.

OSE Immunotherapeutics’ 2026‑28 strategy targets late‑stage cancers, blending ambitious immunotherapy plans with current financial volatility, offering investors a nuanced growth outlook.

Explore OSE Immunotherapeutics’ breakthrough immunotherapies—from phase‑III lung cancer trials to innovative ulcerative colitis treatments—shaping future oncology and inflammation care.

OSE Immuno, a biotechnology company listed on the NYSE Euronext Paris, is a key player in the healthcare sector, with its financial metrics and market activities reflecting its ongoing efforts to innovate and grow.